Varicose eczema: pathogenetic and clinical-pathological aspects. New treatment paradigms with the use of modern venotonic drugs

Abstract

Objective — to analyze current perspectives on the pathogenesis, clinical course characteristics, diagnosis, therapeutic methods for patients with varicose eczema (VE) and to identify further research prospects that will enhance treatment efficacy for the dermatosis in question. Materials and methods. Based on a review of the state-of-the-art literature and our own preliminary investigations, we identified the relevance of deeper investigation of the clinical course details of the varicose eczema and the development of therapy incorporating venotonic drugs in the comprehensive treatment. Results and discussion. Varicose eczema manifests as a chronic relapsing condition occurring alongside chronic venous insufficiency, predominantly affecting the lower extremities and impacting up to 20 % of patients aged over 70. The appointment of venotonic agents to VE patients which improve venous microcirculation and lymphatic drainage, as well as slow down the processes of endothelial dysfunction, thereby increasing the effectiveness of treatment and reducing the likelihood of relapses, is pathogenetically justified.The drug of choice for inclusion in the complex therapy of patients with VE is a modern venotonic agent of combined action Flego®, which includes an ultramicronized fraction of bioflavonoids. Conclusions. Further studies of the mechanisms of development and progression of VE will expand the understanding of the pathogenesis and contribute to the optimization of the therapy of this dermatosis.The appointment of venotonic agents is a pathogenetically justified approach to the treatment of patients with VE.The effectiveness and safety of the venotonic agent of combined action Flego® allows to recommend it for inclusion in the complex treatment schemes of patients with VE.